Syngene International Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹833 Cr −8.6% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
SI

Syngene International Ltd

Q4 FY26Healthcare Services

Syngene International Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,036Cr
+1.8% YoY
+13% QoQ
Net profit
₹148Cr
−19.1% YoY
+886.7% QoQ
Margin
29%
−5 pp YoY
+6 pp QoQ

What the Q4 FY26 call signalled

1 of 3 strong

RevenueSlow growth
MarginMargins steady
CapexCapex planned
Price₹407
Market cap₹16.4K Cr
P/E55.5

The short version

FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up. FY27 is expected to have broadly flat revenue growth with EBITDA margins maintained in the mid-20s % through disciplined cost management.

From Syngene International Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Slow growth
  • FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up.
  • The adverse impact of Librela destocking is expected to continue through H1 FY27, with near-zero Librela volumes anticipated in the first two quarters and only minor volumes thereafter.
  • Post FY27, Syngene expects to reset its baseline and enter a phase of sustainable and higher growth, driven by pipeline maturation and investments in new modalities like peptides, ADCs, and biologics.
  • The company anticipates stronger growth from FY28 onwards as the Librela effect washes out and new capabilities begin to deliver.

2 more points from Syngene International Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Syngene continues to invest in building capabilities and technologies to become an integrated solution provider.
  • In Q4 FY26, invested $10 million focused 50% on research services (capability build, contractual obligations, dedicated centers, and maintenance).
  • About 40% of capex was directed to the CDMO business.
  • The remaining capex was toward digitization, automation, and common infrastructure.
  • Commissioned a new commercial scale facility for liquid-filled hard gelatin capsules, enhancing oral solid dosage capabilities.
  • Expanded Bengaluru biologics facility with a GMP bioconjugation suite for end-to-end antibody drug conjugates manufacturing.
  • Bayview biologics facility in the U.S. is progressing toward operationalization in FY27 with ongoing investments and trial runs.

2 more points from Syngene International Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • It mentions a "healthy pipeline of deal flows" expected to translate into stronger growth from FY28 onwards.
  • Syngene is seeing encouraging interest and increased client interactions at their biologics facilities (Bayview and Unit 3), indicating a growing order pipeline.
  • The extended long-term collaboration with Bristol-Myers Squibb through 2035 suggests a stable and strategic order flow over the next decade.
  • The company is actively engaging with prospective customers as the Bayview biologics facility in the U.S. moves toward operationalization, which supports future order growth.

Syngene International Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Syngene International Ltd Q4 FY26 results — key figures

Syngene International Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,0361,018+1.8%917+13%
Operating profit (EBITDA)303344-11.9%209+45%
Operating margin29%34%-5 pp23%+6 pp
Profit before tax196240-18.3%28+600%
Net profit (PAT)148183-19.1%15+886.7%
EPS (₹)3.674.55-19.3%0.37+891.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹833 Cr, net profit ₹32 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Suven Life Sciences (Q4 FY26)

    The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

  • Invicta Diagnostic (Q4 FY26)

    Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…

  • KMC Speciality (Q4 FY26)

    Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…

  • Star Imaging (Q4 FY26)

    Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Syngene International Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Syngene International Ltd Q4 FY26 results?

FY27 guidance expects broadly flat revenue performance compared to FY26, with growth weighted towards the second half of the year as new contracts ramp up. FY27 is expected to have broadly flat revenue growth with EBITDA margins maintained in the mid-20s % through disciplined cost management.

What is Syngene International Ltd share price analysis?

Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.

Is Syngene International Ltd planning capital expenditure?

Syngene continues to invest in building capabilities and technologies to become an integrated solution provider. - In Q4 FY26, invested $10 million focused 50% on research services (capability build, contractual obligations, dedicated centers, and maintenance). - About 40% of capex was directed to the CDMO business. - The remaining capex was toward digitization, automation, and common infrastructure. - Commissioned a new commercial scale facility for liquid-filled hard gelatin capsules, enhancing oral solid dosage capabilities. - Expanded Bengaluru biologics facility with a GMP bioconjugation suite for end-to-end antibody drug conjugates manufacturing. - Bayview biologics facility in the U.S.

Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.